Narrative reviewcited by the Tayebat archiveabstract only checked A-CHM-18 standard review

Too much chemotherapy close to death is a recognised problem

Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?

Overview

Earle CC et al.. J Clin Oncol 2008 · PMID 18688053 · DOI 10.1200/JCO.2007.15.8253

Review of chemotherapy overuse and late hospice referral in the USA.

Does the study support the specific claim? Yes · Methodological quality: low

Original publication

Plain-language summary

Study explained simply
What did the researchers want to find out?

Review end-of-life care.

How was the study done?

Narrative.

What was actually found?

Overuse trends.

What do the results mean in everyday life?

Plan end-of-life care early.

What are the study's limitations?

Narrative.

What does it say about Elawady's specific claim?

Supports end-of-life point only.

Do the results apply to Germany and Europe?

Low-moderate.

What can explicitly not be concluded from this study?

Curative-setting conclusions.

Scientific in-depth review

1. Full reference

Authors
Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ
Journal
J Clin Oncol
Year
2008
Identifier
PMID 18688053 DOI 10.1200/JCO.2007.15.8253 · PMC2654813
Verification
verified – PubMed E-utilities efetch, 2026-10-25
Retracted
no
Corrections

PubMed lists: ErratumIn (J Clin Oncol. 2010 Jul 1;28(19):3205), ErratumIn (J Clin Oncol. 2011 Nov 20;29(33):4472)

Extent checked
abstract only
Conflicts of interest and funding

not stated in abstract | Grants: NCI NIH HHS

2. Research question

Aggressiveness of cancer care near end of life as a quality issue.

3. Study design and population

Study design
Narrative review – Narrative review with updated analyses
Population

Cancer patients near death (US data)

Country

USA

Period

not applicable

Sample size

not applicable

Inclusion and exclusion criteria

not applicable

4. Methods and endpoints

Exposure / intervention

Chemotherapy near death; hospice use

Comparator

not applicable

Endpoints

Indicators of aggressive care

Statistical methods

not stated

5. Actual results

Results

Discusses trends and factors in chemotherapy overuse near death and hospice underuse (no numbers in abstract).

Absolute risks

not reported in abstract

Authors' conclusion

Whether overly aggressive treatment is a quality-of-care issue is an open question.

6. Strengths

  • Expert synthesis

7. Weaknesses

  • Narrative; no abstract numbers

8. Risk of bias

Orienting tool
none applicable
Type of assessment
simplified assessment (abstract only)
Full formal assessment
no
Overall risk of bias
not assessable
Rationale

Narrative review.

9. Assessment of the statistical interpretation

Not applicable.

10. Relevance to the specific claim

End-of-life context.

11. Independent contrary findings

12. Transferability to Germany and Europe

Low-moderate (US system).

13. Overall methodological judgement

Context citation.

Multidimensional assessment
Multidimensional assessment
Authenticity of the sourceverified
Methodological qualitylow
Risk of biasnot assessable
Precision of resultsnot applicable
Directnessdirect
Reproducibilityunknown
Consistency with the overall evidenceunknown
Regional transferabilitylow
Adequacy of the interpretation (by the archive)essentially correct but incomplete

14. Open questions

15. Linked fact checks

Use by the Tayebat archive

Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.

What the archive says about the study

Listed in bibliography.

A. What was actually studied?

End-of-life aggressiveness.

B. What did the authors find?

Trends of chemo overuse near death.

C. What conclusions do the authors themselves draw?

Open question.

D. What does the archive derive from it?

Over-treatment.

E. Is this derivation scientifically justified?

Appropriate for end-of-life care only.

Adequacy of the interpretation (by the archive)
essentially correct but incomplete